Effect of Zoledronic Acid on Reducing Femoral Bone Mineral Density Loss following Total Hip Arthroplasty : Preliminary Results of a Prospective Randomized Trial |
| |
Authors: | David F. Scott Jennifer N. WoltzRachel R. Smith |
| |
Affiliation: | Spokane Joint Replacement Center, Inc., Spokane, Washington |
| |
Abstract: | This randomized trial evaluated the effect of zoledronic acid on femoral bone mineral density (BMD) following primary total hip arthroplasty. Bone mineral density was compared for up to 2 years in 27 patients receiving 5 mg zoledronic acid intravenous infusion and in 24 patients receiving placebo at 2 weeks and 1 year after surgery. Zoledronic acid prevented loss of bone mineral density at 1 year (+ 13.8% vs + 1.4%, P = .0065) and 2 years (+ 14.3% vs − 4.0%, P < .0001) in Gruen zone 1, at 1 year (− 8.4% vs − 25.4%, P < .0001) and 2 years (− 9.6% vs − 27.3%, P < .0001) in Gruen zone 7, at 6 weeks, 6 months, and 1 or 2 years in Gruen zones 4 and 6. For all Gruen zones, prevention of BMD loss by ZOL was significant at 6 weeks, 6 months, 1 year (+ 0.80% vs − 6.03%, P < .0001) and 2 years (-0.16% vs − 7.13%, P < .0001). |
| |
Keywords: | total hip arthroplasty bone mineral density bisphosphonates |
本文献已被 ScienceDirect 等数据库收录! |
|